CytomX Therapeutics Files 8-K on Corporate Matters
Ticker: CTMX · Form: 8-K · Filed: May 17, 2024 · CIK: 1501989
| Field | Detail |
|---|---|
| Company | Cytomx Therapeutics, INC. (CTMX) |
| Form Type | 8-K |
| Filed Date | May 17, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
CytomX filed an 8-K for corporate updates and voting matters.
AI Summary
CytomX Therapeutics, Inc. filed an 8-K on May 17, 2024, reporting on events that occurred on May 15, 2024. The filing indicates a change in the company's fiscal year end and submission of matters to a vote of security holders, along with financial statements and exhibits. The company is incorporated in Delaware and headquartered in South San Francisco, California.
Why It Matters
This 8-K filing signals important corporate governance and financial reporting updates for CytomX Therapeutics, Inc., which could impact investor understanding of the company's structure and performance.
Risk Assessment
Risk Level: low — This filing is routine corporate disclosure and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- CytomX Therapeutics, Inc. (company) — Registrant
- May 15, 2024 (date) — Earliest event reported
- May 17, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- South San Francisco, California (location) — Principal executive offices
FAQ
What specific corporate matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in this excerpt.
When is the company's fiscal year end?
The filing indicates a change in the fiscal year end, with the previous fiscal year ending on December 31st.
What is the primary business of CytomX Therapeutics, Inc.?
CytomX Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where are CytomX Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 151 Oyster Point Blvd, Suite 400, South San Francisco, California, 94080.
What is the Commission File Number for CytomX Therapeutics, Inc.?
The Commission File Number for CytomX Therapeutics, Inc. is 001-37587.
Filing Stats: 834 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-05-17 16:01:57
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share CTMX Nasdaq Glo
Filing Documents
- d816353d8k.htm (8-K) — 38KB
- d816353dex31.htm (EX-3.1) — 28KB
- 0001193125-24-141699.txt ( ) — 197KB
- ctmx-20240515.xsd (EX-101.SCH) — 3KB
- ctmx-20240515_lab.xml (EX-101.LAB) — 18KB
- ctmx-20240515_pre.xml (EX-101.PRE) — 11KB
- d816353d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Amended and Restated Certificate of Incorporation of CytomX Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYTOMX THERAPEUTICS, INC. Date: May 17, 2024 By: /s/ Lloyd Rowland Lloyd Rowland SVP, General Counsel